DH100 recognizes the companies shaping the future of healthcare innovation in NY

Atropos Health announced today that it has been named to the 2026 New York Digital Health 100 (DH100), an annual recognition honoring the most innovative and high-impact digital health startups in the New York region. Published by Digital Health New York (DHNY), the DH100 is released in conjunction with the 2026 New York Healthcare Innovation Report, which analyzes key investment trends, market dynamics, and opportunities shaping the digital health ecosystem.

Now in its seventh year, the DH100 spotlights the companies driving healthcare forward through bold ideas and scalable solutions. The 2026 list includes 48 new companies addressing some of healthcare’s most complex challenges, alongside members of the DHNY Hall of Fame, which recognizes organizations whose early and lasting contributions helped build New York’s digital health ecosystem.

“Atropos Health is proud to be part of the DH100 list as we continue to drive the adoption of real-world evidence for advancing precision medicine,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “Our work is helping healthcare systems and life sciences organizations make faster, more informed decisions about clinical care, drug development and discovery that ultimately improves patient outcomes.”

“The breadth and depth of companies named to this year’s DH100 reflect a clear market shift from experimentation to execution,” said Bunny Ellerin, co-founder and CEO of DHNY. “These companies are scaling solutions that improve outcomes while building enduring businesses, demonstrating how innovation at the intersection of care delivery, data, and trust is shaping the next generation of healthcare leaders.”

Today’s announcement follows Atropos Health’s launch of Commercial Analytics for life sciences. This is an extension to the already growing number of solutions available to accelerate decision making across the Real World Data(RWD), Research & Development (R&D), Health Economics and Outcomes Research (HEOR)/Medical, and Brand use cases. The solution leverages the speed and accuracy of ChatRWD® to generate rapid answers while transparently displaying actionable insights. Commercial and Brand leaders generate high-quality, brand-specific insights delivered in seconds with not only the visuals they need – but also the data behind the dashboards.

To download a copy of the 2026 New York Healthcare Innovation Report, please click here.

About Atropos Health

Atropos Health is the developer of GENEVA OS®, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improve individual patient outcomes with data-driven care, and expedite research that advances the field of medicine. We aim to transform healthcare with timely, relevant, real-world evidence.

To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or X (Twitter).

About Digital Health New York (DHNY)

Digital Health New York (DHNY) is a connected community of digital health leaders who share ideas, spark new directions and create success across the entire ecosystem. As an organization, DHNY seeks to increase the visibility of New York City as a leader in healthcare innovation and showcase the companies and leaders creating the future of healthcare. Its flagship event, DHNY Summit, brings together an elite group of entrepreneurs, investors, payers, providers and executives to cultivate the New York digital health community and drive impactful conversations around the current and future state of digital health. DHNY was founded in 2022 in collaboration with AlleyCorp. For more information or to join DHNY’s mailing list, please visit www.dhny.co.

DH100 Methodology

To compile the DH100, DHNY invited companies to complete an in-depth application with both quantitative and qualitative measures to get to know the company better. DHNY also used its dynamic database of digital health companies in the region to round out the consideration set. A company qualified for consideration if it maintained headquarters or employed at least 5 people in the New York region. Companies were excluded if: public or non-profit; founded before 2015; on the DH100 five or more years; had an exit. DHNY evaluated companies on a number of factors, including but not limited to: strength of application, leadership, # of employees, funding, revenue, market fit, differentiated offerings, and community engagement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260203443854/en/